EP3097075A2 - Process for preparation of dimethyl-(e)-butenedioate - Google Patents
Process for preparation of dimethyl-(e)-butenedioateInfo
- Publication number
- EP3097075A2 EP3097075A2 EP14812977.8A EP14812977A EP3097075A2 EP 3097075 A2 EP3097075 A2 EP 3097075A2 EP 14812977 A EP14812977 A EP 14812977A EP 3097075 A2 EP3097075 A2 EP 3097075A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- dimethyl
- butenedioate
- reaction mixture
- preparation
- temperature
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 title claims abstract description 56
- 238000000034 method Methods 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims abstract description 60
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract description 42
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000001530 fumaric acid Substances 0.000 claims abstract description 20
- -1 alkanoyl halide Chemical class 0.000 claims abstract description 11
- 239000003054 catalyst Substances 0.000 claims abstract description 11
- 230000008878 coupling Effects 0.000 claims abstract description 9
- 238000010168 coupling process Methods 0.000 claims abstract description 9
- 238000005859 coupling reaction Methods 0.000 claims abstract description 9
- 239000011541 reaction mixture Substances 0.000 claims description 29
- 239000011343 solid material Substances 0.000 claims description 27
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 16
- 238000001816 cooling Methods 0.000 claims description 12
- 239000002245 particle Substances 0.000 claims description 10
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 230000001476 alcoholic effect Effects 0.000 claims description 6
- 239000003960 organic solvent Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- FXXACINHVKSMDR-UHFFFAOYSA-N acetyl bromide Chemical compound CC(Br)=O FXXACINHVKSMDR-UHFFFAOYSA-N 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 238000003109 Karl Fischer titration Methods 0.000 claims description 3
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical group CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 3
- 239000012346 acetyl chloride Substances 0.000 claims description 3
- FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 claims description 2
- NKHAVTQWNUWKEO-UHFFFAOYSA-N fumaric acid monomethyl ester Natural products COC(=O)C=CC(O)=O NKHAVTQWNUWKEO-UHFFFAOYSA-N 0.000 claims description 2
- NKHAVTQWNUWKEO-NSCUHMNNSA-N monomethyl fumarate Chemical compound COC(=O)\C=C\C(O)=O NKHAVTQWNUWKEO-NSCUHMNNSA-N 0.000 claims description 2
- 229940005650 monomethyl fumarate Drugs 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 abstract description 9
- 238000003756 stirring Methods 0.000 description 15
- 229960004419 dimethyl fumarate Drugs 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 238000001035 drying Methods 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 201000004681 Psoriasis Diseases 0.000 description 2
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 2
- VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
- 230000032050 esterification Effects 0.000 description 2
- 238000005886 esterification reaction Methods 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000013341 scale-up Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- BSSNZUFKXJJCBG-OWOJBTEDSA-N (e)-but-2-enediamide Chemical compound NC(=O)\C=C\C(N)=O BSSNZUFKXJJCBG-OWOJBTEDSA-N 0.000 description 1
- KYPOHTVBFVELTG-OWOJBTEDSA-N (e)-but-2-enedinitrile Chemical compound N#C\C=C\C#N KYPOHTVBFVELTG-OWOJBTEDSA-N 0.000 description 1
- 229910015900 BF3 Inorganic materials 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- 108010036781 Fumarate Hydratase Proteins 0.000 description 1
- 241000721701 Lynx Species 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- 239000003377 acid catalyst Substances 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 238000002050 diffraction method Methods 0.000 description 1
- BZCOSCNPHJNQBP-OWOJBTEDSA-N dihydroxyfumaric acid Chemical compound OC(=O)C(\O)=C(/O)C(O)=O BZCOSCNPHJNQBP-OWOJBTEDSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000002237 fumaric acid derivatives Chemical class 0.000 description 1
- 231100000024 genotoxic Toxicity 0.000 description 1
- 230000001738 genotoxic effect Effects 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/48—Separation; Purification; Stabilisation; Use of additives
- C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Definitions
- the present invention relates to a process for preparation of dimethyl-(E)-butenedioate (I).
- the process for preparation of dimethyl-(E)-butenedioate (I) comprises reaction of Fumaric acid with methanol in the presence of C 2 -C4 alkanoyl halide as coupling catalyst.
- Dimethyl-(E)-butenedioate (I) is generally also known as Dimethyl Fumarate and is available commercially as TECDIFERA ® , for the treatment of patients with relapsing forms of multiple sclerosis.
- Dimethyl-(E)-butenedioate is a white to off-white powder that is highly soluble in water with a molecular mass of 144.13
- Fumaric acid is an intermediate in the citric acid cycle that is hydrated by the enzyme fumarase to maleic acid.
- the use of fumaric acid for the treatment of psoriasis was introduced in 1959.
- Earlier known derivatives of fumaric acid like dihydroxy fumaric acid, fumaramide, and fumaronitrile, suffered from problem of insufficient resorbtion, due to which high doses were to be utilized leading to high toxicity and serious side effects.
- Kadowaki, Yasushi; et al. in U.S. Patent Appl. No. 2002/0002306 disclosed a method of producing dimethyl fumarate containing no catalyst residue by use of a heterogenous Group VIII catalyst.
- inventors of the present application provide a process for preparation of dimethyl- (E)-butenedioate, which is amenable to scale up at industrial level and solves purity/ compliance related issues of the end product.
- the process of preparation of dimethyl-(E)-butenedioate (I) comprises the steps of- a) providing a solution of Fumaric acid in methanol at room temperature;
- step f) optionally, treating the solid material obtained in step e) with an organic solvent or a mixture thereof, and recovering the crystalline solid.
- crystalline dimethyl-(E)-butenedioate (I) prepared according to the process of the present invention is having HPLC purity greater than 99.95% (by HPLC) and is characterized by Monomethyl Fumarate content of 0.01% or less.
- the present invention relates to crystalline dimethyl-(E)-butenedioate (I), characterized by X-ray powder diffraction pattern- having at least five 20° peaks selected from the XRPD peak set of 9.82, 10.88, 17.44, 19.81 , 23.71, 23.97, 26.17, 33.26 and 41.26 ⁇ 0.1 °; or substantially according to Fig-1 and DSC isotherm comprising at least one endothermic peak ranging between- a. Peak -1- Between 100 to 110 °C; or
- Fig. 1 is illustration of X-ray powder diffraction ("XRPD") pattern of dimethyl-(E)- butenedioate (I) obtained in Example 1.
- XRPD X-ray powder diffraction
- Fig. 2 is illustration of Differential Scanning Calorimetry ("DSC") curve of dimethyl-(E)- butenedioate (I) obtained in Example 1.
- DSC Differential Scanning Calorimetry
- embodiments of the present invention relate to a process for the preparation of dimethyl-(E)-butenedioate (I),
- step f) optionally, treating the solid material obtained in step e) with an organic solvent or a mixture thereof, and recovering the crystalline solid.
- Step a) comprises providing a solution of Fumaric acid in methanol at room temperature, wherein solution of Fumaric acid is provided in 5-10 volumes of methanol (in mL) w.r.t. weight of Fumaric acid (in g).
- solution of Fumaric acid is provided in 5-10 volumes of methanol (in mL) w.r.t. weight of Fumaric acid (in g).
- 50 g Fumaric acid was provided as solution in 400 mL methanol.
- Step b) comprises adding coupling catalyst C 2 -C4 alkanoyl halide to the reaction mixture, wherein C 2 -C4 alkanoyl halide is added in catalytic amount ranging from 0.35-0.5 moles per 1 mole of Fumaric acid used in step a).
- C 2 -C4 alkanoyl halide is selected from acetyl chloride or acetyl bromide.
- Step c) comprises raising the temperature of reaction mixture up to a range of 50-75 °C;
- the reaction mixture obtained from step b) is heated to temperature ranging from 50-75 °C; preferably up to 60-70 °C.
- the raised reaction temperature is maintained for time duration of 5- 15 hrs depending upon the progress of the reaction as is intermittently checked by HPLC.
- Step d) comprises cooling the reaction mixture to room temperature, wherein cooling is performed in controlled manner of not more than 1 °C/ minute.
- the cooled reaction mass is further subjected to stirring for time duration varying from 1 to 3 hours.
- Step e) comprises isolating the solid material, wherein the solid material separated in step d) is filtered by any method known to person having skill in the art. The solid material is then dried at room temperature for time duration ranging from 1-3 hours.
- Step f) comprises optionally treating the solid material obtained in step e) with an organic solvent or a mixture thereof and recovering the crystalline solid.
- Solid material obtained in step e) is optionally treated with an organic solvent or a mixture thereof.
- the said organic solvent may be selected from C1-C3 alcoholic solvent for e.g. methanol, ethanol or «-propanol.
- Solid material obtained in step e) is dissolved in 8-15 volume C1-C3 alcoholic solvent.
- the reaction mixture is then heated to get a clear solution. Heating is preferably performed to a temperature of 50-60 °C.
- the clear solution is then filtered through celite bed to get a particle free solution, which is again heated if required, to get clear solution. Under continuous stirring the reaction mixture is slowly cooled to RT and then further to a temperature of 0-15 °C, wherein it is maintained for time duration of 1-3 hours.
- the solid material obtained above is filtered and suck dried at room temperature for time ranging from 30 mins to 1 hour. Further drying may be performed under reduced pressure conditions. Reduced pressure conditions may be suitably utilized by person skilled in the art in order to obtain the dried material. In one particular embodiment of the current application, further drying was performed under vacuum. This drying may be performed for time ranging from 2 to 4 hrs depending upon compliance to the product characteristics of dimethyl-(E)- butenedioate (I).
- Process of isolating dimethyl- (E)-butenedioate (I) may further comprise processes but not limited to conventional processes including scrapping and if required filtering from slurry which may be carried out at room temperature for the suitable durations.
- the process related impurities that appear in the impurity profile of dimethyl-(E)-butenedioate (I) may be substantially removed by the process of the present invention resulting in the formation of pure dimethyl-(E)-butenedioate (I) in a crystalline form.
- the merit of the process according to the present invention resides in that - product obtained after drying is highly pure and very stable and can be suitably stored for prolonged durations.
- Substantially pure dimethyl- (E)-butenedioate (I) obtained according to the process of the present invention results in the final API purity by HPLC of more than 99.95 % w/w.
- the final API is characterized by Monomethyl Fu mar ate content of 0.01 % or less.
- the crystalline dimethyl-(E)-butenedioate (I), obtained according to the process of the present invention is characterized by X-ray powder diffraction pattern substantially according to Fig- 1 and DSC isotherm comprising at least one endothermic peak ranging between- a. Peak -1- Between 100 to 110 °C; or
- the crystalline dimethyl-(E)-butenedioate (I), obtained according to the process of the present invention is further characterized by moisture content of less than 0.3 % w/w (Karl Fischer Analysis) and TGA weight loss of less than 0.5 % w/w, up to temperature of 120 °C.
- the crystalline dimethyl-(E)-butenedioate (I), prepared according to the process of the present invention is consistently obtained with particle size, wherein D90 is greater than 250 ⁇ .
- dimethyl-(E)-butenedioate (I) described herein were analyzed by XRPD on a Bruker AXS D8 Advance Diffractometer using X-ray source - Cu Ka radiation using the wavelength 1.5418 A and lynx Eye detector. DSC was done on a Perkin Elmer Pyris 7.0 instrument. Illustrative example of analytical data for dimethyl-(E)-butenedioate (I) obtained in the examples is set forth in the Figs. 1 & 2.
- Example-01 Process for preparation of dimethyl-(E)-butenedioate (I).
- the reaction mixture was further cooled to -15° C under stirring and maintained at this temperature for 2 hours.
- the solid material obtained was filtered and suck dried for 30 mins at RT.
- the solid material was then further dried under vacuum at room temperature for three hours, to obtain 33.2 g dimethyl-(E)-butenedioate (I) in a crystalline form having the XRPD diffractogram and DSC thermogram as shown in Fig. 1 and 2 respectively.
- the crystalline dimethyl-(E)-butenedioate (I) obtained by this process was designated as Form- SD.
- Example-02 Process for preparation of dimethyl-(E)-butenedioate (I).
- the reaction mixture was further cooled to -10° C under stirring and maintained at this temperature for 2 hours.
- the solid material obtained was filtered and suck dried for 30 mins at RT.
- the solid material was then further dried under vacuum at room temperature for three hours, to obtain 26.1 g dimethyl-(E)-butenedioate (I) in a crystalline form having the XRPD diffractogram and DSC thermogram according to Fig. 1 and 2 respectively.
- Example-03 Process for preparation of dimethyl-(E)-butenedioate (I).
- the crystalline dimethyl-(E)-butenedioate (I) obtained by this process was designated as Form- SD.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The present invention relates to a process for preparation of dimethyl-(E)-butenedioate (I). The process for preparation of dimethyl-(E) -but enedioate (I), comprises reaction of Fumaric acid with methanol in the presence of C2-C4 alkanoyl halide as coupling catalyst.
Description
PROCESS FOR PREPARATION OF DIMETHYL-(E)-BUTENEDIOATE
FIELD OF THE INVENTION
The present invention relates to a process for preparation of dimethyl-(E)-butenedioate (I).
The process for preparation of dimethyl-(E)-butenedioate (I), comprises reaction of Fumaric acid with methanol in the presence of C2-C4 alkanoyl halide as coupling catalyst.
INTRODUCTION
Dimethyl-(E)-butenedioate (I) is generally also known as Dimethyl Fumarate and is available commercially as TECDIFERA®, for the treatment of patients with relapsing forms of multiple sclerosis.
Dimethyl-(E)-butenedioate is a white to off-white powder that is highly soluble in water with a molecular mass of 144.13
Fumaric acid is an intermediate in the citric acid cycle that is hydrated by the enzyme fumarase to maleic acid. The use of fumaric acid for the treatment of psoriasis was introduced in 1959. Earlier known derivatives of fumaric acid like dihydroxy fumaric acid, fumaramide, and fumaronitrile, suffered from problem of insufficient resorbtion, due to which high doses were to be utilized leading to high toxicity and serious side effects.
Gamrath et al in US2764609 described conversion of dialkyl maleate to dialkyl fumarate by heating around 100 °C in presence of phosphorus oxychloride, thionyl chloride or phosphorus trichloride etc. and then cooling.
Further the literature article in journal Synthesis, Issue 6, Pages 316-17 (1971) provided a method of esterification of unsaturated organic acids using a boron trifluoride etherate-alcohol reagents, thereby synthesizing dimethyl-(E)-butenedioate.
U.S. Patent Nos. US 4851439, US 4959389 and US 5424332 provided further disclosure of fumaric acid derivatives and their pharmaceutical compositions for the treatment of psoriasis and psoriatic arthritis.
Kadowaki, Yasushi; et al. in U.S. Patent Appl. No. 2002/0002306 disclosed a method of producing dimethyl fumarate containing no catalyst residue by use of a heterogenous Group VIII catalyst.
The single- crystal structure of dimethyl fumarate is disclosed in Kooijman, H., et al, Acta Crystallographica £60:0917-0918 (2004).
Guzowski et al in WO2012170923 Al described a process for the preparation of dimethyl Fumarate, involving the esterification of fumaric acid and methanol in the presence of sulfuric acid as an acid catalyst. It is mentioned that the dimethyl fumarate obtained by the mentioned process contained no more than trace amounts of dimethyl sulfate.
Though the review of the above mentioned literature discloses diverse processes for preparation of dimethyl-(E)-butenedioate, but due to one or more reasons most of them are not particularly convenient and amenable to industrial scale-up. Thus, there is an apparent need of new improved processes for preparation of dimethyl-(E)-butenedioate, which may be efficient, cost-effective, industrially scalable and may overcome the drawbacks of various prior disclosed processes, e.g., use of corrosive chemicals in large quantity.
Therefore, inventors of the present application provide a process for preparation of dimethyl- (E)-butenedioate, which is amenable to scale up at industrial level and solves purity/ compliance related issues of the end product.
SUMMARY OF INVENTION
Particular aspects of the present specification relate to the process for the preparation of dimethyl-(E)-butenedioate (I).
The process of preparation of dimethyl-(E)-butenedioate (I) comprises the steps of- a) providing a solution of Fumaric acid in methanol at room temperature;
b) adding coupling catalyst C2-C4 alkanoyl halide to the reaction mixture;
c) raising the temperature of reaction mixture up to a range of 50-75 °C;
d) cooling the reaction mixture;
e) isolating the solid material;
f) optionally, treating the solid material obtained in step e) with an organic solvent or a mixture thereof, and recovering the crystalline solid.
One aspect of the present invention provides that crystalline dimethyl-(E)-butenedioate (I) prepared according to the process of the present invention is having HPLC purity greater than 99.95% (by HPLC) and is characterized by Monomethyl Fumarate content of 0.01% or less.
In a further aspect, the present invention relates to crystalline dimethyl-(E)-butenedioate (I), characterized by X-ray powder diffraction pattern- having at least five 20° peaks selected from the XRPD peak set of 9.82, 10.88, 17.44, 19.81 , 23.71, 23.97, 26.17, 33.26 and 41.26 ± 0.1 °; or substantially according to Fig-1 and DSC isotherm comprising at least one endothermic peak ranging between- a. Peak -1- Between 100 to 110 °C; or
b. Peak -2- Between 135 to 155 °C.
Another aspect of the present invention provides crystalline dimethyl-(E)-butenedioate (I), characterized by moisture content of less than 0.3 % w/w (Karl Fischer Analysis), TGA weight loss of less than 0.5 % w/w, up to temperature of 120 °C and particle size distribution of D90 = 252-280 μπι.
Further particular aspects of the invention are detailed in the description part of the specification, wherever appropriate.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is illustration of X-ray powder diffraction ("XRPD") pattern of dimethyl-(E)- butenedioate (I) obtained in Example 1.
Fig. 2 is illustration of Differential Scanning Calorimetry ("DSC") curve of dimethyl-(E)- butenedioate (I) obtained in Example 1.
ABBREVIATIONS
DETAILED DESCRIPTION
As set forth herein, embodiments of the present invention relate to a process for the preparation of dimethyl-(E)-butenedioate (I),
comprising the steps of:
a) providing a solution of Fumaric acid in methanol at room temperature;
b) adding coupling catalyst C2-C4 alkanoyl halide to the reaction mixture;
c) raising the temperature of reaction mixture up to a range of 50-75 °C;
d) cooling the reaction mixture;
e) isolating the solid material;
f) optionally, treating the solid material obtained in step e) with an organic solvent or a mixture thereof, and recovering the crystalline solid.
The individual steps of the process according to the present invention for preparing dimethyl- (E)-butenedioate (I), are detailed separately herein below.
Step a) comprises providing a solution of Fumaric acid in methanol at room temperature, wherein solution of Fumaric acid is provided in 5-10 volumes of methanol (in mL) w.r.t. weight of Fumaric acid (in g). In a particular embodiment of the present invention 50 g Fumaric acid was provided as solution in 400 mL methanol.
Step b) comprises adding coupling catalyst C2-C4 alkanoyl halide to the reaction mixture, wherein C2-C4 alkanoyl halide is added in catalytic amount ranging from 0.35-0.5 moles per 1 mole of Fumaric acid used in step a). In a preferred embodiment C2-C4 alkanoyl halide is selected from acetyl chloride or acetyl bromide.
Use of coupling catalyst, C2-C4 alkanoyl halide in the process of the present invention bears the inventive merit of avoiding the use of corrosive chemicals like Sulphuric acid and thus also negates the possibility of formation of toxic impurities like dimethyl sulphate.
Step c) comprises raising the temperature of reaction mixture up to a range of 50-75 °C;
The reaction mixture obtained from step b) is heated to temperature ranging from 50-75 °C; preferably up to 60-70 °C. The raised reaction temperature is maintained for time duration of 5- 15 hrs depending upon the progress of the reaction as is intermittently checked by HPLC.
Step d) comprises cooling the reaction mixture to room temperature, wherein cooling is performed in controlled manner of not more than 1 °C/ minute. The cooled reaction mass is further subjected to stirring for time duration varying from 1 to 3 hours.
Step e) comprises isolating the solid material, wherein the solid material separated in step d) is filtered by any method known to person having skill in the art. The solid material is then dried at room temperature for time duration ranging from 1-3 hours.
Step f) comprises optionally treating the solid material obtained in step e) with an organic solvent or a mixture thereof and recovering the crystalline solid.
Solid material obtained in step e) is optionally treated with an organic solvent or a mixture thereof. The said organic solvent may be selected from C1-C3 alcoholic solvent for e.g. methanol, ethanol or «-propanol. Solid material obtained in step e) is dissolved in 8-15 volume C1-C3 alcoholic solvent. The reaction mixture is then heated to get a clear solution. Heating is preferably performed to a temperature of 50-60 °C. The clear solution is then filtered through celite bed to get a particle free solution, which is again heated if required, to get clear solution. Under continuous stirring the reaction mixture is slowly cooled to RT and then further to a temperature of 0-15 °C, wherein it is maintained for time duration of 1-3 hours.
The solid material obtained above is filtered and suck dried at room temperature for time ranging from 30 mins to 1 hour. Further drying may be performed under reduced pressure conditions. Reduced pressure conditions may be suitably utilized by person skilled in the art in order to obtain the dried material. In one particular embodiment of the current application, further drying was performed under vacuum. This drying may be performed for time ranging from 2 to 4 hrs depending upon compliance to the product characteristics of dimethyl-(E)- butenedioate (I).
Process of isolating dimethyl- (E)-butenedioate (I) may further comprise processes but not limited to conventional processes including scrapping and if required filtering from slurry which may be carried out at room temperature for the suitable durations.
With increasing emphasis on safety of the pharmaceutical substances, regulatory agencies demand stringent in process mechanisms for determination and the control of DNA reactive (mutagenic) impurities/ genotoxic impurities in medicinal products.
The process related impurities that appear in the impurity profile of dimethyl-(E)-butenedioate (I) may be substantially removed by the process of the present invention resulting in the formation of pure dimethyl-(E)-butenedioate (I) in a crystalline form. The merit of the process according to the present invention resides in that - product obtained after drying is highly pure and very stable and can be suitably stored for prolonged durations. Substantially pure dimethyl- (E)-butenedioate (I) obtained according to the process of the present invention results in the final API purity by HPLC of more than 99.95 % w/w. The final API is characterized by Monomethyl Fu mar ate content of 0.01 % or less.
The crystalline dimethyl-(E)-butenedioate (I), obtained according to the process of the present invention is characterized by X-ray powder diffraction pattern substantially according to Fig- 1 and DSC isotherm comprising at least one endothermic peak ranging between- a. Peak -1- Between 100 to 110 °C; or
b. Peak -2- Between 135 to 155 °C.
The characteristic peaks and the corresponding d-spacing values of the crystalline dimethyl-(E)-butenedioate (I) obtained by the process of the present invention are tabulated in the Table- 1 and is designated as Form-SD.
Table-1
Minor variations in the observed 2 θ° angles values may be expected based on the analyst person, the specific XRPD diffractometer employed and the sample preparation technique. Further possible variations may also be expected for the relative peak intensities, which may be largely affected by the non-uniformity of the particle size of the sample. Hence, identification of the exact crystalline form of a compound should be based primarily on observed 2 theta
angles with lesser importance attributed to relative peak intensities. The 2 theta diffraction angles and corresponding d-spacing values account for positions of various peaks in the X-ray powder diffraction pattern. D-spacing values are calculated with observed 2 theta angles and copper K a wavelength using the Bragg equation well known to those of having skill in the art of XRPD diffractometry science.
The crystalline dimethyl-(E)-butenedioate (I), obtained according to the process of the present invention is further characterized by moisture content of less than 0.3 % w/w (Karl Fischer Analysis) and TGA weight loss of less than 0.5 % w/w, up to temperature of 120 °C.
The crystalline dimethyl-(E)-butenedioate (I), prepared according to the process of the present invention is consistently obtained with particle size, wherein D90 is greater than 250 μπι. Preferably particle size of crystalline dimethyl-(E)-butenedioate (I) obtained according to the process of current invention, ranges between D90 = 252-280 μπι. This uniform particle size distribution of the final API which is suitable for handling and further processing is achieved directly by the process of the present invention and obviates the need for any type of milling procedure to be performed. Thus process of the present invention has advantage of directly providing the material suitable for making pharmaceutical compositions, having acceptable and comparable dissolution profiles.
The samples of dimethyl-(E)-butenedioate (I) described herein were analyzed by XRPD on a Bruker AXS D8 Advance Diffractometer using X-ray source - Cu Ka radiation using the wavelength 1.5418 A and lynx Eye detector. DSC was done on a Perkin Elmer Pyris 7.0 instrument. Illustrative example of analytical data for dimethyl-(E)-butenedioate (I) obtained in the examples is set forth in the Figs. 1 & 2.
EXAMPLES
Example-01: Process for preparation of dimethyl-(E)-butenedioate (I).
In a clean round bottom flask 50.0 g fumaric acid and 400.0 mL methanol, were charged under stirring at room temperature. Then under stirring, 14.6 g acetyl chloride was added slowly to the reaction mixture. The reaction temperature was raised to 70° C and maintained for 12 hours, followed by cooling to room temperature and further stirring for one hour. The separated
solid material was filtered and suck dried for two hours at room temperature. 45.0 g of the dried solid material was charged to 540.0 mL methanol at room temperature and then heated to ~ 55° C to get the clear solution. The clear solution was filtered through celite bed to get the particle free solution. The clear solution was again heated to ~ 55 ° C and then cooled to room temperature under stirring. The reaction mixture was further cooled to -15° C under stirring and maintained at this temperature for 2 hours. The solid material obtained was filtered and suck dried for 30 mins at RT. The solid material was then further dried under vacuum at room temperature for three hours, to obtain 33.2 g dimethyl-(E)-butenedioate (I) in a crystalline form having the XRPD diffractogram and DSC thermogram as shown in Fig. 1 and 2 respectively.
HPLC purity: 99.97%
Moisture content: 0.09 % w/w
The crystalline dimethyl-(E)-butenedioate (I) obtained by this process was designated as Form- SD.
Example-02: Process for preparation of dimethyl-(E)-butenedioate (I).
In a clean round bottom flask 40.0 g fumaric acid and 330.0 mL methanol, were charged under stirring at room temperature. Then under stirring, 34.0 g acetyl bromide was added slowly to the reaction mixture. The reaction temperature was raised to 65° C and maintained for 12 hours, followed by cooling to room temperature and further stirring for one hour. The separated solid material was filtered and suck dried for two hours at room temperature. 35.0 g of the dried solid material was charged to 450.0 mL ethanol at room temperature and then heated to ~ 50° C to get the clear solution. The clear solution was filtered through celite bed to get the particle free solution. The clear solution was again heated to ~ 55° C and then cooled to room temperature under stirring. The reaction mixture was further cooled to -10° C under stirring and maintained at this temperature for 2 hours. The solid material obtained was filtered and suck dried for 30 mins at RT. The solid material was then further dried under vacuum at room temperature for three hours, to obtain 26.1 g dimethyl-(E)-butenedioate (I) in a crystalline form having the XRPD diffractogram and DSC thermogram according to Fig. 1 and 2 respectively.
HPLC purity: 99.98%
Moisture content: 0.15 % w/w
The crystalline dimethyl-(E)-butenedioate (I) obtained by this process was designated as Form- SD.
Example-03: Process for preparation of dimethyl-(E)-butenedioate (I).
In a clean round bottom flask 40.0 g fumaric acid and 330.0 mL methanol, were charged under stirring at room temperature. Then under stirring, 34.0 g acetyl bromide was added slowly to the reaction mixture. The reaction temperature was raised to 65-70° C and maintained for 14 hours, followed by cooling to 10-15°C and further stirring for one hour. The separated solid material was filtered and suck dried for one hour at room temperature. Dried the material for 4- 5 hours under vacuum at room temperature and check the moisture content (NMT 0.50 w/w). 35.0 g of the dried solid material was charged to 450.0 mL methanol at room temperature and then heated to 60-65 °C to get the clear solution. The clear solution was filtered through hyflow bed to get the particle free solution and washed with methanol. Distilled off methanol under vacuum at 40-45°C. Cooled the reaction mixture to 0-5°C and again stirred for 2-3 hours. Filtered the solid and dried for 1 hour at room temperature. Dried the material at 25-35°C for 4- 5 hours. The obtained dimethyl-(E)-butenedioate (I) in a crystalline form having the XRPD diffractogram and DSC thermogram according to Fig. 1 and 2 respectively.
HPLC purity: 99.99%
Moisture content: 0.21 % w/w
The crystalline dimethyl-(E)-butenedioate (I) obtained by this process was designated as Form- SD.
While the foregoing pages provide a detailed description of the preferred embodiments of the invention, it is to be understood that the description and examples are illustrative only of the principles of the invention and not limiting. Furthermore, as many changes can be made to the invention without departing from the scope of the invention, it is intended that all material contained herein be interpreted as illustrative of the invention and not in a limiting sense.
Claims
Claims:
1) A process for the preparation of dimethyl-(E)-butenedioate (I),
comprising the steps of:
a) providing a solution of Fumaric acid in methanol at room temperature;
b) adding coupling catalyst C2-C4 alkanoyl halide to the reaction mixture;
c) raising the temperature of reaction mixture up to a range of 50-75 °C;
d) cooling the reaction mixture;
e) isolating the solid material; and
f) optionally treating the solid material obtained in step e) with an organic solvent or a mixture thereof, and recovering the crystalline solid.
2) A process for the preparation of dimethyl-(E)-butenedioate (I) according to claim 1 , wherein, in step a) solution of Fumaric acid is provided in 5-10 volumes of methanol (in mL) w.r.t. weight of Fumaric acid (in g).
3) A process for the preparation of dimethyl-(E)-butenedioate (I) according to claim 1 , wherein, coupling catalyst C2-C4 alkanoyl halide is selected from acetyl chloride or acetyl bromide, and is used in quantity of 0.35-0.5 moles per mole of Fumaric acid.
4) A process for the preparation of dimethyl-(E)-butenedioate (I) according to claim 1 , wherein, in step c) reaction mixture temperature is raised up to 60-70 °C.
5) A process for the preparation of dimethyl-(E)-butenedioate (I) according to claim 1 , wherein, optional step f) comprises treatment of the solid material obtained in step e) with Q- C3 alcoholic solvent and involves the steps of- i. providing a solution of solid material obtained in step e) with 8-15 volume C1-C3 alcoholic solvent;
ii. heating the reaction mixture to temperature of 50-60 °C;
iii. cooling the reaction mixture to a temperature of 0-15 °C; and
iv. recovering the crystalline solid.
6) A process for the preparation of dimethyl-(E)-butenedioate (I) according to claim 5, wherein, C1-C3 alcoholic solvent is selected from methanol, ethanol or «-propanol.
7) Crystalline dimethyl-(E)-butenedioate (I) characterized by X-ray powder diffraction pattern- having at least five 20° peaks selected from the XRPD peak set of 9.82, 10.88, 17.44, 19.81 , 23.71 , 23.97, 26.17, 33.26 and 41.26 ± 0.1 °; or substantially according to Fig-1 and DSC isotherm comprising at least one endothermic peak ranging between- a. Peak -1- Between 100 to 110 °C; or
b. Peak -2- Between 135 to 155 °C.
8) A process for the preparation of dimethyl-(E)-butenedioate (I) characterized by X-ray powder diffraction pattern-having at least five diffraction angle peaks (20°) selected from the XRPD peak set of 9.82, 10.88, 17.44, 19.81 , 23.71, 23.97, 26.17, 33.26 and 41.26 ± 0.1 ° and DSC isotherm comprising at least one endothermic peak ranging between 100 to 110 °C (peak-1); and 135 to 155 °C(peak-2) comprising the steps of:
a) providing a solution of Fumaric acid in methanol at room temperature;
b) adding coupling catalyst C2-C4 alkanoyl halide to the reaction mixture;
c) raising the temperature of reaction mixture up to a range of 50-75 °C;
d) cooling the reaction mixture;
e) isolating the solid material;
f) providing a solution of solid material obtained in step e) with 8-15 volume C1-C3 alcoholic solvent;
g) heating the reaction mixture to temperature of 50-60 °C;
h) cooling the reaction mixture to a temperature of 0-15 °C; and
i) recovering the crystalline solid.
9) Crystalline dimethyl-(E)-butenedioate (I), according to claim 8, further characterized by moisture content of less than 0.3 % w/w (Karl Fischer Analysis).
10) Crystalline dimethyl-(E)-butenedioate (I) characterized by presence of Monomethyl Fumarate, to an extent of 0.01 % or less (by HPLC) and particle size distribution of D90 = 252-280 μπι.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IB2014/065440 WO2014203231A2 (en) | 2014-01-24 | 2014-10-18 | Process for preparation of dimethyl-(e)-butenedioate |
| IN308CH2014 IN2014CH00308A (en) | 2014-01-24 | 2014-10-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP3097075A2 true EP3097075A2 (en) | 2016-11-30 |
| EP3097075A4 EP3097075A4 (en) | 2017-06-21 |
Family
ID=52105418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP14812977.8A Withdrawn EP3097075A4 (en) | 2014-01-24 | 2014-10-18 | Process for preparation of dimethyl-(e)-butenedioate |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP3097075A4 (en) |
| IN (1) | IN2014CH00308A (en) |
| WO (1) | WO2014203231A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017013672A1 (en) | 2015-07-23 | 2017-01-26 | Natco Pharma Ltd | Process for the preparation of pharmaceutical grade dimethyl fumarate |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3078302A (en) * | 1958-09-25 | 1963-02-19 | Monsanto Chemicals | Production of dialkyl fumarates |
| US3905943A (en) * | 1973-04-16 | 1975-09-16 | Koppers Co Inc | Preparation of fumarates |
| PE20141639A1 (en) * | 2011-06-08 | 2014-11-08 | Biogen Idec Inc | PROCESS FOR PREPARING CRYSTALLINE HIGH PURITY DIMETHYL SMOKE |
| CN102766050A (en) * | 2012-08-10 | 2012-11-07 | 太仓市运通化工厂 | Method for synthesizing dimethyl fumarate |
-
2014
- 2014-10-18 IN IN308CH2014 patent/IN2014CH00308A/en unknown
- 2014-10-18 WO PCT/IB2014/065440 patent/WO2014203231A2/en active Application Filing
- 2014-10-18 EP EP14812977.8A patent/EP3097075A4/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3097075A4 (en) | 2017-06-21 |
| WO2014203231A2 (en) | 2014-12-24 |
| WO2014203231A3 (en) | 2015-07-30 |
| IN2014CH00308A (en) | 2015-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1916251A1 (en) | Erianin salts, their preparation methods and pharmaceutical compositions containing the same | |
| JP3974939B2 (en) | Process for producing aminoethylethanolamine and / or hydroxyethylpiperazine | |
| CN106589039B (en) | preparation method of obeticholic acid and related compound | |
| AU2017331930B2 (en) | Crystalline forms | |
| WO1997047588A1 (en) | Method of preparing quaternary trialkanolamine ester salts | |
| CN106565672A (en) | Method for preparation of Efinaconazole | |
| CN110305163A (en) | Tenofovir Chinese mugwort draws the preparation method of phenol amine hemifumarate | |
| WO2014203231A2 (en) | Process for preparation of dimethyl-(e)-butenedioate | |
| US7385068B2 (en) | Stearate composition and method | |
| CN110831944B (en) | Method for preparing sitagliptin by preparing intermediate 2,4, 5-trifluoro-phenylacetic acid | |
| JP5622842B2 (en) | Method for producing alkylamine derivative | |
| US20160326087A1 (en) | Process for preparation of dimethyl-(e)-butenedioate | |
| CN113480574B (en) | Recycling method of phosphorus-containing compound salt | |
| CN110759848A (en) | Ethanesulfonic acid nintedanib impurity as well as preparation method and application thereof | |
| CN105585511B (en) | (R) preparation method of N tertbutyloxycarbonyls biphenyl Propanolamine | |
| JP6761564B2 (en) | L-proline compound of sodium-glucose cotransporter 2 inhibitor, and monohydrate and crystal of L-proline compound | |
| CN114369061A (en) | Preparation method of clonazepam related substance B | |
| CN110981911A (en) | Preparation method of tenofovir alafenamide | |
| WO2021255429A1 (en) | Process for preparing n,n-dimethyl-4-((6-oxopyrimidin-1(6h)-yl)methyl)benzamide from 4-((6-oxopyrimidin-1(6h)-yl)methyl)benzoic acid, and crystalline forms of the benzamide | |
| CN114181203B (en) | Preparation method of thiamine hydrochloride, application and vitamin B1 | |
| CN112778177A (en) | High-quality fudosteine impurity standard substance and preparation method thereof | |
| WO2020048343A1 (en) | Synthesis method for 6-furfurylaminopurine | |
| KR102816950B1 (en) | Method of forming phthalate-based ester compound | |
| CN106132973B (en) | The preparation of the phosphorous acid diamide of purifying | |
| CN113527106B (en) | Preparation method of pharmaceutical grade sitagliptin chloride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| 17P | Request for examination filed |
Effective date: 20160809 |
|
| AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| AX | Request for extension of the european patent |
Extension state: BA ME |
|
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20170524 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07C 69/40 20060101AFI20170518BHEP |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
| 18D | Application deemed to be withdrawn |
Effective date: 20171223 |